Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model

Clinical and Diagnostic Laboratory Immunology

Volumn 6, Issue 4, 1999, Pages 464-470

  Bruss, Jon B ^a,b   Siber, George R ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PERTUSSIS TOXIN;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MORTALITY; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PROVOCATION TEST; WEIGHT GAIN;

EID: 0032810796     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.6.4.464-470.1999     Document Type: Article

References (63)

1. Ad Hoc Group for the Study of Pertussis Vaccines. 1988. Placebo-controlled trial of two acellular pertussis vaccines in Sweden - protective efficacy and adverse events. Lancet i:955-960.
2. Ad Hoc Group for the Study of Pertussis Vaccines. 1997. A randomized controlled trial of a two-component, a three-component and a five-component acellular pertussis vaccine and a British whole-cell pertussis vaccine. Lancet 350:1569-1577.
3. Adler, A., and S. I. Morse. 1973. Interaction of lymphoid and nonlymphoid cells with the lymphocytosis-promoting factor of Bordetella pertussis. Infect. Immun. 7:461-467.
4. Ausiello, C. M., F. Urbani, A. La Sala, R. Lande, and A. Cassone. 1997. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect. Immun. 65:2168-2174.
5. Balagtas, R. C., K. E. Nelson, S. Levin, and S. P. Gotoff. 1971. Treatment of pertussis with pertussis immune globulin. J. Pediatr. 79:203-208.
6. Barnard, A., B. P. Mahon, J. Watkins, K. Redhead, and K. H. G. Mills. 1996. Th1,Th2 cell dichotomy in acquired immunity to Bordetella pertussis: variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T cell subsets as Th1, Th2 or Th0. Immunology 87:372-380.
7. Bass, J. W. 1986. Erythromycin for treatment and prevention of pertussis. Pediatr. Infect. Dis. J. 5:154-157.
8. Bivin, W. S., and G. D. Smith. 1984. Techniques of experimentation, p. 565-566. In J. G. Fox, B. J. Cohen, and F. M. Loew (ed.), Laboratory animal medicine. Academic Press, Inc., New York, N.Y.
9. Blackwelder, W. C. 1990. Vaccine efficacy for a variety of clinical case definitions. Food and Drug Administration publication no. 260. U.S. Government Printing Office, Washington, D.C.
10. Bradford, W. L. 1935. Use of convalescent blood in whooping cough. With a review of the literature. Am. J. Dis. Child. 50:918-923.
11. Bromberg, K., G. Tannis, and P. Steiner. 1991. Detection of Bordetella pertussis associated with the alveolar macrophages of children with human immunodeficiency virus infection. Infect. Immun. 59:4715-4719.
12. Cassone, A., C. M. Ausiello, F. Urbani, R. Lande, and S. Giuliano for the Progetto Pertosse-CMI Working Group. 1997. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Arch. Pediatr. Adolesc. Med. 151:283-289.
13. Centers for Disease Control and Prevention. 1990. Pertussis surveillance -United States, 1986-1988. Morbid. Mortal. Weekly Rep. 39:57-66.
14. Centers for Disease Control and Prevention. 1992. Pertussis surveillance -United States, 1989-1991. Morbid. Mortal. Weekly Rep. 41:11-19.
15. Centers for Disease Control and Prevention. 1995. Pertussis surveillance -United States, 1992-1995. Morbid. Mortal. Weekly Rep. 44:525-529.
16. Centers for Disease Control and Prevention. 1993. Resurgence of pertussis - United States, 1993. Morbid. Mortal. Weekly Rep. 42:952-960.
17. Christie, C., and R. S. Baltimore. 1989. Pertussis in neonates. Am. J. Dis. Child. 143:1199-1202.
18. Dellepiane, N. I., M. A. Manghi, P. V. Eriksson, G. Di Paola, and A. Cangelosi. 1992. Pertussis whole cell vaccines: relation between intracerebral protection in mice and antibody response to pertussis, filamentous hemagglutinin and adenylate cyclase. Int. J. Med. Microbiol. Virol. Parasitol. Infect. Dis. 277:65-73.
19. Edwards, K. M., B. D. Meade, M. D. Decker, G. F. Reed, M. B. Rennels, M. C. Steinhoff, E. L. Anderson, J. A. Enguland, M. E. Pichichero, and M. A. Deloria. 1995. Comparison of thirteen acellular pertussis vaccines: overview and serological response. Pediatrics 96:548-557.
20. Ferngren, H., and M. Granström. 1986. Antitoxin in human pertussis immune globulins. J. Biol. Stand. 14:297-303.
21. Fujiwara, H., and S. Iwasa. 1989. The quantitative assay of the clustering activity of the lymphocytosis-promoting factor (pertussis toxin) of Bordetella pertussis on Chinese hamster ovary (CHO) cells. J. Biol. Stand. 17:53-64.
22. Gillenius, P., E. Jäätmaa, P. Askelöf, M. Granström, and M. Tiru. 1985. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J. Biol. Stand. 13:61-66.
23. Granström, M., A. M. Olinder-Nielsen, P. Holmblad, A. Mark, and K. Hanngren. 1991. Specific immunoglobulin for treatment of whooping cough. Lancet 38:1230-1233.
24. Greco, D., S. Salmaso, P. Mastrantonio, M. Guiliano, A. G. Tozzi, A. Anemona, M. L. Giori Degli Atti, A. Giammanco, P. Panel, W. C. Blackwelder, D. L. Klein, S. G. F. Wassilak, and the Progetto Pertosse Working Group. 1996. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334:341-348.
25. Gupta, R. K., S. N. Saxena, B. S. Suniti, and S. Ahuja. 1988. The effects of purified pertussis components and lipopolysaccharide on the results of the mouse weight gain test. J. Biol. Stand. 16:321-331.
26. Gupta, R. K., S. N. Saxena, and S. B. Sharma. 1990. Protection of mice inoculated with purified pertussis toxins and filamentous haemagglutinin against intracerebral challenge with Bordetella pertussis. Vaccine 8:289.
27. Gustafsson, L., H. O. Hallander, P. Olin, E. Reizenstein, and J. Storsaeter. 1996. A controlled trial of a two-component acellular, a five component acellular, and a whole cell pertussis vaccine. N. Engl. J. Med. 334:349-355.
28. Halperin, S. A., S. A. Heifetz, and A. Kasina. 1988. Experimental respiratory infection with Bordetella pertussis in mice: comparison of two methods. Clin. Investig. Med. 11:297-303.
29. Hink, J. H., Jr., and F. F. Johnson. 1950. The occurrence in human plasma fractions of the antibodies to H. pertussis. J. Immunol. 64:39-43.
30. Mahon, B. P., M. Ryan, F. Griffin, and K. H. G. Mills. 1996. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells. Infect. Immunogy 64:5295-5301.
31. Mahon, B. P., F. Griffin, B. Sheahan, and K. H. G. Mills. 1997. Atypical disease following Bordetella pertussis respiratory infection of mice with targeted disruptions in IFN-receptor or immunoglobulin μ chain genes. J. Exp. Med. 186:1843-1851.
32. McGregor, J., J. W. Ogle, and G. Curry-Kane. 1986. Perinatal pertussis. Obstet. Gynecol. 68:582-585.
33. McGuinness, A. C., J. G. Armstrong, and H. M. Felton. 1944. Hyperimmune whooping cough serum. J. Pediatr. 24:249-258.
34. McGuinness, A. C., W. L. Bradford, and J. G. Armstrong. 1940. The production and use of hyperimmune human whooping cough serum. J. Pediatr. 16:21-29.
35. Miller, E., L. A. E. Ashworth, K. Redhead, C. Thornton, P. A. Waight, and T. Coleman. 1997. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine 15:51-60.
36. Mills, K. H. G., A. Barnard, J. Watkins, and K. Redhead. 1993. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect. Immun. 61:399-410.
37. Mills, K. H. G., A. Barnard, J. Watkins, and K. Redhead. 1998. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66:594-602.
38. Morris, D., and J. C. McDonald. 1957. Failure of hyperimmune gamma globulin to prevent whooping cough. Arch. Dis. Child. 32:236-239.
39. Oda, M., J. L. Cowell, and D. G. Burstyn. 1984. Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice. J. Infect. Dis. 150:6823-6833.
40. Olin, P., and J. Storsaeter. 1989. The efficacy of acellular pertussis vaccines. JAMA 261:560.
41. Olson, L. C. 1975. Pertussis. Medicine 54:427-469.
42. Pittman, M. 1984. The concept of pertussis as a toxin-mediated disease. Pediatr. Infect. Dis. J. 3:467-486.
43. Pittman, M., B. L. Furman, and A. C. Wardlaw. 1980. Bordetella pertussis respiratory tract infection in the mouse: pathophysiological responses. J. Infect. Dis. 142:56-66.
44. Pittman, M., R. A. Gardner, and J. E. Marshall. 1979. Evaluation of the potency of anti-pertussis serum products. J. Biol. Stand. 7:263-273.
45. Redhead, K., A. Barnard, J. Watkins, and K. H. G. Mills. 1993. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on the induction of cell-mediated immunity. Infect. Immun. 61: 3190-3198.
46. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
47. Robinson, A., A. Gorringe, and M. Fernandez. 1989. Serospecific protection of mice against intranasal infection with Bordetella pertussis. Vaccine 7:321-324.
48. Ryan, M., G. Murphy, L. Gothefors, L. Nilsson, J. Storsaeter, and K. H. G. Mills. 1997. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 Th cells. J. Infect. Dis. 175:1246-1250.
49. Ryan, M., L. Gothefors, J. Storsaeter, and K. H. G. Mills. 1997. B. pertussis-specific Th1/Th2 cells generated following respiratory infection or immunization with an acellular vaccine: comparison of the T cell cytokine profiles in infants and mice. Dev. Biol. Stand. 89:251-259.
50. Ryan, M., G. Murphy, L. Nilsson, F. Shackley, L. Gothefors, K. Ømar, E. Miller, J. Storsaeter, and K. H. G. Mills. 1998. Distinct Th cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93:1-10.
51. Sato, H., A. Ito, J. Chiba, and Y. Sato. 1984. Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections. Infect. Immun. 46:422-428.
52. Sato, H., and Y. Sato. 1984. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect. Immun. 46:415-421.
53. Sato, H., and Y. Sato. 1988. Pathogenesis and immunity in pertussis, p. 309-325. In Animal models of pertussis. John Wiley & Sons, Ltd., London, United Kingdom.
54. Sato, H., and Y. Sato. 1990. Protective activities in mice of monoclonal antibodies against pertussis toxin. Infect. Immun. 58:3369-3374.
55. Sato, Y., K. Izumiya, H. Sato, J. L. Cowell, and C. R. Manclark. 1981. Role of antibody to leukocytosis promoting factor, hemagglutinin and to filamentous hemagglutinin in immunity to pertussis. Infect. Immun. 31:1223-1231.
56. Sato, Y., K. Izumiya, H. Sato, J. L. Cowell, and C. R. Manclark. 1980. Aerosol infection of mice with Bordetella pertussis. Infect. Immun. 29:261-266.
57. Sato, Y., I. Kazumi, H. Sato, J. L. Cowell, and C. R. Manclark. 1985. Role of antibody to filamentous hemagglutinin and to leukocytosis promoting factor-hemagglutinin in immunity to pertussis. Semin. Infect. Dis. 4:380-385.
58. Scheinblum, I. E., and J. G. Bullowa. 1944. The treatment of pertussis with lyophile hyperimmune human pertussis serum. J. Pediatr. 25:49-55.
59. Siber, G. R., N. Thakrar, and B. A. Yancey. 1991. Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children. Vaccine 9:735-740.
60. Simondon, F., M. P. Preziosi, A. Yam, C. T. Kane, L. Chabirand, I. Iteman, G. Sanden, S. Mboup, A. Hoffenbach, K. Knudsen, N. Guiso, S. Wassilak, and M. Cadoz. 1997. A randomized double blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15:1606-1612.
61. Standfast, A. F. B. 1958. The comparison between field trials and mouse protection tests against intranasal and intracerebral challenges with Bordetella pertussis. Immunology. 2:135.
62. Trollofors, B., J. Taranger, T. Lagergard, L. Lind, V. Sundh, G. Zackrisson, C. U. Lowe, W. Blackwelder, and J. B. Robbins. 1995. A placebo-controlled trial of a pertussis-toxoid vaccine. N. Engl. J. Med. 333:1045-1050.
63. Zollinger, W. D., and J. W. Boslego. 1981. A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class-specific antibodies. J. Immunol. Methods 46:129-140.